Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Diabetes Reports
Erschienen in: Current Diabetes Reports 12/2018

01.12.2018 | Pathogenesis of Type 1 Diabetes (A Pugliese and SJ Richardson, Section Editors)

The Environmental Determinants of Diabetes in the Young (TEDDY) Study: 2018 Update

verfasst von: Marian Rewers, Heikki Hyöty, Åke Lernmark, William Hagopian, Jin-Xiong She, Desmond Schatz, Anette-G Ziegler, Jorma Toppari, Beena Akolkar, Jeffrey Krischer, the TEDDY Study Group

Erschienen in: Current Diabetes Reports | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The environmental triggers of islet autoimmunity leading to type 1 diabetes (T1D) need to be elucidated to inform primary prevention. The Environmental Determinants of Diabetes in the Young (TEDDY) Study follows from birth 8676 children with T1D risk HLA-DR-DQ genotypes in the USA, Finland, Germany, and Sweden. Most study participants (89%) have no first-degree relative with T1D. The primary outcomes include the appearance of one or more persistent islet autoantibodies (islet autoimmunity, IA) and clinical T1D.

Recent Findings

As of February 28, 2018, 769 children had developed IA and 310 have progressed to T1D. Secondary outcomes include celiac disease and autoimmune thyroid disease. While the follow-up continues, TEDDY has already evaluated a number of candidate environmental triggers, including infections, probiotics, micronutrient, and microbiome.

Summary

TEDDY results suggest that there are multiple pathways leading to the destruction of pancreatic beta-cells. Ongoing measurements of further specific exposures, gene variants, and gene-environment interactions and detailed “omics” studies will provide novel information on the pathogenesis of T1D.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Group DERI. Secular trends in incidence of childhood IDDM in 10 countries. Diabetes. 1990;39(7):858–64.CrossRef
2.
Patterson CC, Dahlquist GG, Gyurus E, Green A, Soltesz G. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005–20: a multicentre prospective registration study. Lancet. 2009;373(9680):2027–33.PubMedCrossRef
3.
Mayer-Davis EJ, Lawrence JM, Dabelea D, Divers J, Isom S, Dolan L, et al. Incidence trends of type 1 and type 2 diabetes among youths, 2002–2012. N Engl J Med. 2017;376(15):1419–29.PubMedPubMedCentralCrossRef
4.
5.
6.
TEDDY Study Group. The Environmental Determinants of Diabetes in the Young (TEDDY) study: study design. Pediatr Diabetes. 2007;8(5):286–98.CrossRef
7.
TEDDY Study Group. The Environmental Determinants of Diabetes in the Young (TEDDY) study. Ann N Y Acad Sci. 2008;1150:1–13.PubMedCentralCrossRef
8.•
Lonnrot M, Lynch KF, Elding Larsson H, et al. Respiratory infections are temporally associated with initiation of type 1 diabetes autoimmunity: the TEDDY study. Diabetologia. 2017;60(10):1931–40. TEDDY reports that respiratory infections increase the risk of islet autoimmunity in young children. Islet autoimmunity developed in 454 out of 7869 high-risk children followed from birth. Each infection in a 9-month period increased the subsequent risk of autoimmunity by 6%. PubMedPubMedCentralCrossRef
9.
Uusitalo U, Liu X, Yang J, Aronsson CA, Hummel S, Butterworth M, et al. Association of early exposure of probiotics and islet autoimmunity in the TEDDY study. JAMA Pediatr. 2016;170(1):20–8.PubMedPubMedCentralCrossRef
10.
11.
Lundgren M, Steed LJ, Tamura R, et al. Analgesic antipyretic use among young children in the TEDDY study: no association with islet autoimmunity. BMC Pediatr. 2017;17(1):127.PubMedPubMedCentralCrossRef
12.
Ziegler AG, Pflueger M, Winkler C, Achenbach P, Akolkar B, Krischer JP, et al. Accelerated progression from islet autoimmunity to diabetes is causing the escalating incidence of type 1 diabetes in young children. J Autoimmun. 2011;37(1):3–7.PubMedPubMedCentralCrossRef
13.
Hummel S, Beyerlein A, Tamura R, Uusitalo U, Andrén Aronsson C, Yang J, et al. First infant formula type and risk of islet autoimmunity in The Environmental Determinants of Diabetes in the Young (TEDDY) study. Diabetes Care. 2017;40(3):398–404.PubMedPubMedCentralCrossRef
14.
Elding Larsson H, Vehik K, Haller MJ, Liu X, Akolkar B, Hagopian W, et al. Growth and risk for islet autoimmunity and progression to type 1 diabetes in early childhood: The Environmental Determinants of Diabetes in the Young study. Diabetes. 2016;65(7):1988–95.PubMedPubMedCentralCrossRef
15.
Elding Larsson H, Lynch KF, Lonnrot M, et al. Pandemrix(R) vaccination is not associated with increased risk of islet autoimmunity or type 1 diabetes in the TEDDY study children. Diabetologia. 2018;61(1):193–202.PubMedCrossRef
16.
Beyerlein A, Liu X, Uusitalo UM, Harsunen M, Norris JM, Foterek K, et al. Dietary intake of soluble fiber and risk of islet autoimmunity by 5 y of age: results from the TEDDY study. Am J Clin Nutr. 2015;102(2):345–52.PubMedPubMedCentralCrossRef
17.
Torn C, Hadley D, Lee HS, et al. Role of type 1 diabetes-associated SNPs on risk of autoantibody positivity in the TEDDY study. Diabetes. 2015;64(5):1818–29.PubMedCrossRef
18.
Torn C, Liu X, Hagopian W, et al. Complement gene variants in relation to autoantibodies to beta cell specific antigens and type 1 diabetes in the TEDDY study. Sci Rep. 2016;6:27887.PubMedPubMedCentralCrossRef
19.
Sharma A, Liu X, Hadley D, Hagopian W, Chen WM, Onengut-Gumuscu S, et al. Identification of non-HLA genes associated with development of islet autoimmunity and type 1 diabetes in the prospective TEDDY cohort. J Autoimmun. 2018;89:90–100.PubMedCrossRefPubMedCentral
20.
Krischer JP, Liu X, Lernmark A, Hagopian WA, Rewers MJ, She JX, et al. The influence of type 1 diabetes genetic susceptibility regions, age, sex, and family history on the progression from multiple autoantibodies to type 1 diabetes: a TEDDY study report. Diabetes. 2017;66(12):3122–9.PubMedPubMedCentralCrossRef
21.
Bonifacio E, Beyerlein A, Hippich M, Winkler C, Vehik K. Genetic scores to stratify risk of developing multiple islet autoantibodies and type 1 diabetes: a prospective study in children. PLoS Med. 2018;15(4):e1002548.PubMedPubMedCentralCrossRef
22.•
Norris JM, Lee HS, Frederiksen B, Erlund I, Uusitalo U, Yang J, et al. Plasma 25-hydroxyvitamin D concentration and risk of islet autoimmunity. Diabetes. 2018;67(1):146–54. TEDDY provides evidence for a protective effect of higher plasma vitamin D levels for development of islet autoimmunity in high-risk children. However, this protective effect is limited to children who carry specific vitamin D receptor genotypes. PubMedCrossRef
23.
Lynch KF, Lee HS, Torn C, et al. Gestational respiratory infections interacting with offspring HLA and CTLA-4 modifies incident beta-cell autoantibodies. J Autoimmun. 2018;86:93–103.PubMedCrossRef
24.•
Krischer JP, Lynch KF, Lernmark A, Hagopian WA, Rewers MJ, She JX, et al. Genetic and environmental interactions modify the risk of diabetes-related autoimmunity by 6 years of age: the TEDDY study. Diabetes Care. 2017;40(9):1194–202. TEDDY demonstrates an apparent heterogeneity of type 1 diabetes and the underlying genetic and environmental determinants. PubMedPubMedCentralCrossRef
25.
Russell CD, Baillie JK. Treatable traits and therapeutic targets: goals for systems biology in infectious disease. Curr Opin Syst Biol. 2017;2:140–6.CrossRefPubMedPubMedCentral
26.
Hagopian WA, Erlich H, Lernmark A, Rewers M, Ziegler AG, Simell O, et al. The environmental determinants of diabetes in the young (TEDDY): genetic criteria and international diabetes risk screening of 421 000 infants. Pediatr Diabetes. 2011;12(8):733–43.PubMedPubMedCentralCrossRef
27.
Cucca F, Lampis R, Frau F, Macis D, Angius E, Masile P, et al. The distribution of DR4 haplotypes in Sardinia suggests a primary association of type I diabetes with DRB1 and DQB1 loci. Hum Immunol. 1995;43(4):301–8.PubMedCrossRef
28.
29.
Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964–74.PubMedPubMedCentralCrossRef
30.
Vehik K, Fiske SW, Logan CA, Agardh D, Cilio CM, Hagopian W, et al. Methods, quality control and specimen management in an international multicentre investigation of type 1 diabetes: TEDDY. Diabetes Metab Res Rev. 2013;29(7):557–67.PubMedPubMedCentral
31.
American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care. 2017;40(Suppl 1):S11–24.CrossRef
32.
Elding Larsson H, Vehik K, Gesualdo P, Akolkar B, Hagopian W, Krischer J, et al. Children followed in the TEDDY study are diagnosed with type 1 diabetes at an early stage of disease. Pediatr Diabetes. 2014;15(2):118–26.PubMedCrossRef
33.
Elding Larsson H, Vehik K, Bell R, Dabelea D, Dolan L, Pihoker C, et al. Reduced prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up. Diabetes Care. 2011;34(11):2347–52.PubMedPubMedCentralCrossRef
34.
Steck AK, Larsson HE, Liu X, Veijola R, Toppari J, Hagopian WA, et al. Residual beta-cell function in diabetes children followed and diagnosed in the TEDDY study compared to community controls. Pediatr Diabetes. 2017;18(8):794–802.PubMedPubMedCentralCrossRef
35.
Harjutsalo V, Sund R, Knip M, Groop PH. Incidence of type 1 diabetes in Finland. JAMA. 2013;310(4):427–8.PubMedCrossRef
36.
Bendas A, Rothe U, Kiess W, Kapellen TM, Stange T, Manuwald U, et al. Trends in incidence rates during 1999-2008 and prevalence in 2008 of childhood type 1 diabetes mellitus in Germany—model-based national estimates. PLoS One. 2015;10(7):e0132716.PubMedPubMedCentralCrossRef
37.
Hanberger L, Birkebaek N, Bjarnason R, Drivvoll AK, Johansen A, Skrivarhaug T, et al. Childhood diabetes in the Nordic countries: a comparison of quality registries. J Diabetes Sci Technol. 2014;8(4):738–44.PubMedPubMedCentralCrossRef
38.
Lee HS, Briese T, Winkler C, et al. Next-generation sequencing for viruses in children with rapid-onset type 1 diabetes. Diabetologia. 2013;56(8):1705–11.PubMedPubMedCentralCrossRef
39.
Vehik K, Lynch KF, Schatz DA, Akolkar B, Hagopian W, Rewers M, et al. Reversion of beta-cell autoimmunity changes risk of type 1 diabetes: TEDDY study. Diabetes Care. 2016;39(9):1535–42.PubMedPubMedCentralCrossRef
40.
Steck AK, Vehik K, Bonifacio E, Lernmark A, Ziegler AG, Hagopian WA, et al. Predictors of progression from the appearance of islet autoantibodies to early childhood diabetes: The Environmental Determinants of Diabetes in the Young (TEDDY). Diabetes Care. 2015;38(5):808–13.PubMedPubMedCentralCrossRef
41.
Yu L, Dong F, Miao D, Fouts AR, Wenzlau JM, Steck AK. Proinsulin/insulin autoantibodies measured with electrochemiluminescent assay are the earliest indicator of prediabetic islet autoimmunity. Diabetes Care. 2013;36(8):2266–70.PubMedPubMedCentralCrossRef
42.
Yu LZ, Miao D, Waugh K, Jiang L, Steck A, Liu L, et al. Electrochemiluminescence-based IAA and GADA assays detect the appearance of islet autoimmunity earlier than radioimmunoassay in a significant proportion of children. San Francisco: Immunology of Diabetes Society; 2017.
43.
Kohler M, Beyerlein A, Vehik K, et al. Joint modeling of longitudinal autoantibody patterns and progression to type 1 diabetes: results from the TEDDY study. Acta Diabetol. 2017;54(11):1009–17.PubMedPubMedCentralCrossRef
44.
Ilonen J, Hammais A, Laine AP, Lempainen J, Vaarala O, Veijola R, et al. Patterns of beta-cell autoantibody appearance and genetic associations during the first years of life. Diabetes. 2013;62(10):3636–40.PubMedPubMedCentralCrossRef
45.
Ziegler AG, Bonifacio E. Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia. 2012;55(7):1937–43.PubMedCrossRef
46.
Ziegler AG, Hummel M, Schenker M, Bonifacio E. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB study. Diabetes. 1999;48(3):460–8.PubMedCrossRef
47.
Hagopian WA, Sanjeevi CB, Kockum I, Landin-Olsson M, Karlsen AE, Sundkvist G, et al. Glutamate decarboxylase-, insulin-, and islet cell-antibodies and HLA typing to detect diabetes in a general population-based study of Swedish children. J Clin Invest. 1995;95(4):1505–11.PubMedPubMedCentralCrossRef
48.
Krischer JP, Lynch KF, Schatz DA, et al. The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia. 2015;58(5):980–7.PubMedPubMedCentralCrossRef
49.
de Goffau MC, Luopajarvi K, Knip M, Ilonen J, Ruohtula T, Harkonen T, et al. Fecal microbiota composition differs between children with beta-cell autoimmunity and those without. Diabetes. 2013;62:1238–44.PubMedPubMedCentralCrossRef
50.
Parkes M, Cortes A, van Heel DA, Brown MA. Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat Rev Genet. 2013;14(9):661–73.PubMedCrossRef
51.
52.
53.
Roepstorff K, Grovdal L, Grandal M, Lerdrup M, van Deurs B. Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer. Histochem Cell Biol. 2008;129(5):563–78.PubMedPubMedCentralCrossRef
54.
Muller D, Telieps T, Eugster A, et al. Novel minor HLA DR associated antigens in type 1 diabetes. Clin Immunol. 2018;194:87–91.PubMedCrossRef
55.
Bian X, Wasserfall C, Wallstrom G, Wang J, Wang H, Barker K, et al. Tracking the antibody immunome in type 1 diabetes using protein arrays. J Proteome Res. 2017;16(1):195–203.PubMedCrossRef
56.
Ziegler AG, Danne T, Dunger DB, Berner R, Puff R, Kiess W, et al. Primary prevention of beta-cell autoimmunity and type 1 diabetes—the Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) perspectives. Mol Metab. 2016;5(4):255–62.PubMedPubMedCentralCrossRef
57.
Hommel A, Haupt F, Delivani P, Winkler C, Stopsack M, Wimberger P, et al. Screening for type 1 diabetes risk in newborns: the Freder1k pilot study in Saxony. Horm Metab Res. 2018;50(1):44–9.PubMedCrossRef
58.
Lonnrot M, Lynch K, Larsson HE, et al. A method for reporting and classifying acute infectious diseases in a prospective study of young children: TEDDY. BMC Pediatr. 2015;15:24.PubMedPubMedCentralCrossRef
59.
Kemppainen KM, Lynch KF, Liu E, Lönnrot M, Simell V, Briese T, et al. Factors that increase risk of celiac disease autoimmunity after a gastrointestinal infection in early life. Clin Gastroenterol Hepatol. 2017;15(5):694–702.e695.PubMedCrossRef
60.
Kemppainen KM, Vehik K, Lynch KF, Larsson HE, Canepa RJ, Simell V, et al. Association between early-life antibiotic use and the risk of islet or celiac disease autoimmunity. JAMA Pediatr. 2017;171(12):1217–25.PubMedPubMedCentralCrossRef
61.
Salami F, Abels M, Hyoty H, et al. Detection of Latobacilli in monthly mail-in stool samples from 3–18 months old infants at genetic risk for type 1 diabetes. Int Journal of Probiotics Prebiotics. 2012;7(3–4):135–44.
62.
Stewart CJ, Ajami NJ, O’Brien JL, et al. Temporal development of the gut microbiome in early childhood from the TEDDY study. Nature. 2018;563.
63.
Vatanen T, Franzosa EA, Schwager R, et al. The human gut microbiome of early onset type 1 diabetes from the TEDDY study. Nature. 2018;563.
64.
Sioofy-Khojine A-B, Oikarinen S, Honkanen H, Huhtala H, Lehtonen JP, Briese T, et al. Molecular epidemiology of enteroviruses in young children at increased risk of type 1 diabetes. PLoS One. 2018;13:e0201959.PubMedPubMedCentralCrossRef
65.
Nurminen N, Oikarinen S, Hyoty H. Virus infections as potential targets of preventive treatments for type 1 diabetes. Rev Diabet Stud. 2012;9(4):260–71.PubMedCrossRef
66.
Uusitalo U, Kronberg-Kippila C, Aronsson CA, Schakel S, Schoen S, Mattisson I, et al. Food composition database harmonization for between-country comparisons of nutrient data in the TEDDY study. J Food Compost Anal. 2011;24(4–5):494–505.PubMedPubMedCentralCrossRef
67.
Joslowski G, Yang J, Aronsson CA, Ahonen S, Butterworth M, Rautanen J, et al. Development of a harmonized food grouping system for between-country comparisons in the TEDDY study. J Food Compost Anal. 2017;63:79–88.PubMedPubMedCentralCrossRef
68.
Aronsson CA, Vehik K, Yang J, Uusitalo U, Hay K, Joslowski G, et al. Use of dietary supplements in pregnant women in relation to sociodemographic factors—a report from The Environmental Determinants of Diabetes in the Young (TEDDY) study. Public Health Nutr. 2013;16(8):1390–402.PubMedPubMedCentralCrossRef
69.
Andren Aronsson C, Uusitalo U, Vehik K, et al. Age at first introduction to complementary foods is associated with sociodemographic factors in children with increased genetic risk of developing type 1 diabetes. Matern Child Nutr. 2015;11(4):803–14.PubMedCrossRef
70.
Hummel S, Vehik K, Uusitalo U, McLeod W, Aronsson CA, Frank N, et al. Infant feeding patterns in families with a diabetes history—observations from The Environmental Determinants of Diabetes in the Young (TEDDY) birth cohort study. Public Health Nutr. 2014;17(12):2853–62.PubMedCrossRef
71.
Yang J, Tamura RN, Uusitalo UM, Aronsson CA, Silvis K, Riikonen A, et al. Vitamin D and probiotics supplement use in young children with genetic risk for type 1 diabetes. Eur J Clin Nutr. 2017;71(12):1449–54.PubMedPubMedCentralCrossRef
72.
Niinistö SEI, Lee H-S, Uusitalo U, Salminen I, Aronsson CA, Hummel S, et al. Higher EPA and DPA status in erythrocyte during infancy is associated with reduced risk of islet autoimmunity. San Francisco: Immunologu of Diabetes Society; 2017.
73.
Hyppönen E, Virtanen SM, Kenward MG, Knip M, Akerblom HK, Childhood Diabetes in Finland Study Group. Obesity, increased linear growth, and risk of type 1 diabetes in children. Diabetes Care. 2000;23(12):1755–60.
74.
Knip M, Reunanen A, Virtanen SM, Nuutinen M, Viikari J, Akerblom HK. Does the secular increase in body mass in children contribute to the increasing incidence of type 1 diabetes? Pediatr Diabetes. 2008;9(3 Pt 2):46–9.PubMedCrossRef
75.
Wilkin TJ. The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes. Diabetologia. 2001;44(7):914–22.PubMedCrossRef
76.
Dahlquist G. Can we slow the rising incidence of childhood-onset autoimmune diabetes? The overload hypothesis. Diabetologia. 2006;49(1):20–4.PubMedCrossRef
77.
Hagopian W, Lee HS, Liu E, Rewers M, She JX, Ziegler AG, et al. Co-occurrence of type 1 diabetes and celiac disease autoimmunity. Pediatrics. 2017;140(5):e20171305.PubMedCrossRef
78.
Liu E, Lee HS, Aronsson CA, Hagopian WA, Koletzko S, Rewers MJ, et al. Risk of pediatric celiac disease according to HLA haplotype and country. N Engl J Med. 2014;371(1):42–9.PubMedPubMedCentralCrossRef
79.
Agardh D, Lee HS, Kurppa K, Simell V, Aronsson CA, Jorneus O, et al. Clinical features of celiac disease: a prospective birth cohort. Pediatrics. 2015;135(4):627–34.PubMedPubMedCentralCrossRef
80.
Sharma A, Liu X, Hadley D, Hagopian W, Liu E, Chen WM, et al. Identification of non-HLA genes associated with celiac disease and country-specific differences in a large, international pediatric cohort. PLoS One. 2016;11(3):e0152476.PubMedPubMedCentralCrossRef
81.
Hadley D, Hagopian W, Liu E, et al. HLA-DPB1*04:01 protects genetically susceptible children from celiac disease autoimmunity in the TEDDY study. Am J Gastroenterol. 2015;110(6):915–20.PubMedPubMedCentralCrossRef
82.
Andren Aronsson C, Lee HS, Koletzko S, et al. Effects of gluten intake on risk of celiac disease: a case-control study on a Swedish birth cohort. Clin Gastroenterol Hepatol. 2016;14(3):403–409.e403.PubMedCrossRef
83.
Aronsson CA, Lee HS, Liu E, Uusitalo U, Hummel S, Yang J, et al. Age at gluten introduction and risk of celiac disease. Pediatrics. 2015;135(2):239–45.PubMedPubMedCentralCrossRef
84.
Johnson SB, Lynch KF, Roth R, Schatz D. My child is islet autoantibody positive: impact on parental anxiety. Diabetes Care. 2017;40(9):1167–72.PubMedPubMedCentralCrossRef
85.
Swartling U, Lynch K, Smith L, Johnson SB. Parental estimation of their child’s increased type 1 diabetes risk during the first 2 years of participation in an international observational study: results from the TEDDY study. J Empir Res Hum Res Ethics. 2016;11(2):106–14.PubMedPubMedCentralCrossRef
86.
Roth R, Lynch K, Lernmark B, Baxter J, Simell T, Smith L, et al. Maternal anxiety about a child’s diabetes risk in the TEDDY study: the potential role of life stress, postpartum depression, and risk perception. Pediatr Diabetes. 2015;16(4):287–98.PubMedCrossRef
87.
Smith LB, Lynch KF, Baxter J, Lernmark B, Roth R, Simell T, et al. Factors associated with maternal-reported actions to prevent type 1 diabetes in the first year of the TEDDY study. Diabetes Care. 2014;37(2):325–31.PubMedPubMedCentralCrossRef
88.
Johnson SB, Lynch KF, Baxter J, Lernmark B, Roth R, Simell T, et al. Predicting later study withdrawal in participants active in a longitudinal birth cohort study for 1 year: the TEDDY study. J Pediatr Psychol. 2016;41(3):373–83.PubMedCrossRef
89.
Lernmark B, Lynch K, Baxter J, et al. Participant experiences in the environmental determinants of diabetes in the young study: common reasons for withdrawing. J Diabetes Res. 2016;2720650:2016.
90.
Haghighi M, Johnson SB, Qian X, Lynch KF, Vehik K, Huang S. A comparison of rule-based analysis with regression methods in understanding the risk factors for study withdrawal in a pediatric study. Sci Rep. 2016;6:30828.PubMedPubMedCentralCrossRef
91.
Yang J, Lynch KF, Uusitalo UM, Foterek K, Hummel S, Silvis K, et al. Factors associated with longitudinal food record compliance in a paediatric cohort study. Public Health Nutr. 2016;19(5):804–13.PubMedCrossRef
92.
Johnson SB, Lynch KF, Lee HS, Smith L, Baxter J, Lernmark B, et al. At high risk for early withdrawal: using a cumulative risk model to increase retention in the first year of the TEDDY study. J Clin Epidemiol. 2014;67(6):609–11.PubMedPubMedCentralCrossRef
93.
Lernmark B, Lynch K, Ballard L, et al. Reasons for staying as a participant in the environmental determinants of diabetes in the young (TEDDY) longitudinal study. J Clin Trials. 2012;2(2).
94.
Baxter J, Vehik K, Johnson SB, Lernmark B, Roth R, Simell T. Differences in recruitment and early retention among ethnic minority participants in a large pediatric cohort: the TEDDY study. Contemp Clin Trials. 2012;33(4):633–40.PubMedPubMedCentralCrossRef
Metadaten
Titel
The Environmental Determinants of Diabetes in the Young (TEDDY) Study: 2018 Update
verfasst von
Marian Rewers
Heikki Hyöty
Åke Lernmark
William Hagopian
Jin-Xiong She
Desmond Schatz
Anette-G Ziegler
Jorma Toppari
Beena Akolkar
Jeffrey Krischer
the TEDDY Study Group
Publikationsdatum
01.12.2018
Verlag
Springer US
Erschienen in
Current Diabetes Reports / Ausgabe 12/2018
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-018-1113-2

Weitere Artikel der Ausgabe 12/2018

Current Diabetes Reports 12/2018 Zur Ausgabe

Lifestyle Management to Reduce Diabetes/Cardiovascular Risk (B Conway and H Keenan, Section Editors)

A Review of Data of Findings on Night Shift Work and the Development of DM and CVD Events: a Synthesis of the Proposed Molecular Mechanisms

Lifestyle Management to Reduce Diabetes/Cardiovascular Risk (B Conway and H Keenan, Section Editors)

Fat Versus Carbohydrate-Based Energy-Restricted Diets for Weight Loss in Patients With Type 2 Diabetes

Therapies and New Technologies in the Treatment of Diabetes (M Pietropaolo, Section Editor)

Effect of Health Information Technologies on Glycemic Control Among Patients with Type 2 Diabetes

Hospital Management of Diabetes (A Wallia and JJ Seley, Section Editors)

Innovations in Professional Inpatient Diabetes Education

Microvascular Complications—Neuropathy (R Pop-Busui, Section Editor)

Blood Pressure Variability and Autonomic Dysfunction

Therapies and New Technologies in the Treatment of Diabetes (M Pietropaolo, Section Editor)

Gut Microbiome in Obesity, Metabolic Syndrome, and Diabetes

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise